Novartis has unveiled a dazzling multi-billion dollar business deal which sees it divest its vaccines and animal health divisions, build its oncology portfolio, and create a new joint venture ...

Novartis carries a solid financial position with a debt/EBITDA ratio of 1.5 times. Further, its diverse portfolio of drugs should translate into steady cash flows to easily service debt requirements.

Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal ...

Novartis's current payout ratio is 31% ... From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety ...

Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

“This is a meaningful addition to our renal portfolio as we continue driving innovation in kidney care, following our recent ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be ...

Novartis announces acquisition of Regulus Therapeutics, adding a potential first-in-class miR-17 inhibitor for ADPKD to its ...

LONDON (Reuters) -Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of ...